Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 2, Issue 10, Pages e95-e95
Publisher
Springer Nature
Online
2012-10-19
DOI
10.1038/bcj.2012.30
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
- (2012) H. J. Khoury et al. BLOOD
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
- (2012) David Montani et al. CIRCULATION
- Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia
- (2011) Prasanth Ganesan et al. AMERICAN JOURNAL OF HEMATOLOGY
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
- (2011) Karl J. Aichberger et al. AMERICAN JOURNAL OF HEMATOLOGY
- Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia
- (2011) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
- (2011) A. R. Ibrahim et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Expanding Nilotinib Access in Clinical Trials (ENACT)
- (2011) Franck E. Nicolini et al. CANCER
- The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
- (2011) C. A. Eide et al. CANCER RESEARCH
- Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
- (2011) D. Dumitrescu et al. EUROPEAN RESPIRATORY JOURNAL
- Severe Peripheral Arterial Disease During Nilotinib Therapy
- (2011) P. Le Coutre et al. JNCI-Journal of the National Cancer Institute
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis
- (2011) Franck E. Nicolini et al. LEUKEMIA & LYMPHOMA
- Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia
- (2011) Ester M. Orlandi et al. LEUKEMIA RESEARCH
- Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
- (2011) Jan K Hennigs et al. BMC Pulmonary Medicine
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
- (2010) H. M. Kantarjian et al. BLOOD
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed
- (2010) Lina Eliasson et al. LEUKEMIA RESEARCH
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Drug Toxicities in Chronic Myeloid Leukaemia
- (2009) Michael J. Mauro et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
- (2009) L. Noens et al. BLOOD
- The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
- (2009) David Masiello et al. Journal of Hematology & Oncology
- Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient
- (2008) D Mattei et al. BONE MARROW TRANSPLANTATION
- Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia
- (2008) Walid Rasheed et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started